Firefly Neuroscience (NASDAQ:AIFF) Stock Price Down 8.2% – Here’s What Happened

Firefly Neuroscience, Inc. (NASDAQ:AIFF)’s share price fell 8.2% on Monday . The company traded as low as $0.6175 and last traded at $0.6380. 88,535 shares changed hands during mid-day trading, an increase of 25% from the average session volume of 70,587 shares. The stock had previously closed at $0.6950.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Firefly Neuroscience has a consensus rating of “Sell”.

Firefly Neuroscience Price Performance

The stock’s fifty day moving average price is $0.97 and its 200 day moving average price is $1.84. The stock has a market capitalization of $9.07 million, a P/E ratio of -0.31 and a beta of 1.91.

Institutional Trading of Firefly Neuroscience

A number of large investors have recently modified their holdings of AIFF. Geode Capital Management LLC grew its stake in Firefly Neuroscience by 92.9% in the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after purchasing an additional 58,067 shares in the last quarter. Savvy Advisors Inc. purchased a new stake in shares of Firefly Neuroscience in the 3rd quarter worth $63,000. Vanguard Group Inc. grew its position in shares of Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after buying an additional 401,085 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Firefly Neuroscience during the fourth quarter valued at $53,000. Hedge funds and other institutional investors own 4.96% of the company’s stock.

About Firefly Neuroscience

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.